Software & SaaS

New 2025 data reveals an AI platform is slashing costs, improving chronic disease outcomes, and closing health equity gaps for hundreds of clinicians.

Progyny signals better-than-expected 2025 results on robust member engagement, sparking analyst upgrades and sending its stock soaring ahead of a key conference.

Kyle Addington of American Wealth Advisers joins IFG's new advisory council, giving local clients a voice in the future of financial services nationwide.

As McGraw Hill execs prep for a key investor conference, all eyes are on their digital-first strategy and how they'll navigate the AI-driven EdTech boom.

MediKarma is licensing autonomous AI agents to manage disease and data, aiming to become the core processor for the entire healthcare industry.

With a new board member and strategic investment, Kandu, Inc. is set to scale its brain-computer interface technology for stroke recovery.

The wellness firm secured a cash infusion by repricing options, a move that provides vital funds for its Zola brand but raises questions about dilution.

Offerpad raises $18M in a direct offering. The move aims to bolster its finances and fund a strategic pivot to asset-light services in a changing market.

NYU Langone and tech firm Tempus are launching a new protocol using serial DNA sequencing and AI to create hyper-personalized cancer treatments.

Carlsmed's AI-driven aprevo® platform shows massive surgeon adoption and market growth, signaling a new era of personalized, cost-effective spine care.

The supply chain tech leader appoints a seasoned marketing exec from Drift and Salesforce to accelerate its next growth phase and amplify its AI strategy.

A new study reveals payment failures cost billions as customer patience runs out in minutes, creating a crisis for retail and hospitality brands.

The EdTech giant is unveiling an integrated ecosystem with new AI capabilities and a Microsoft Teams solution at five major international trade shows.

After a strategic pivot reverses a year of decline, Allurion's preliminary results show new growth. All eyes are now on the FDA for its 'procedureless' gastric balloon.

ConcertAI and Foundation Medicine unite to create a huge dataset of 500k patients, using AI to accelerate the hunt for new life-saving cancer drugs.

FDA clears a novel two-part immunotherapy that paints solid tumors with a synthetic target, unleashing a powerful CAR T-cell attack in a new clinical trial.

Promising new 96-week data shows Vir's therapy could redefine care for severe hepatitis delta, as its oncology pipeline and financial runway also advance.

Moderna CEO Stephane Bancel joins CFS's board, signaling a major push to commercialize fusion energy. Can his vaccine scale-up success crack the code?

The insurance giant landed a major credit facility, calming investor nerves and doubling down on its fast-growing pharmacy and healthcare services arm.

Erasca reports promising early data for its pan-RAS inhibitor, ERAS-0015, showing tumor shrinkage at low doses and shaking up the competitive landscape.